drugset / Trial / NCT02375555
Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MM
NaSingle-groupOpen-labelTreatment
Summary
This research study is evaluating a combination of four drugs -- lenalidomide, bortezomib, dexamethasone and elotuzumab -- as therapy for newly diagnosed multiple myeloma.
Timeline
- Start
- 2015-05-07
- Primary completion
- 2021-12-15
- Completion
- 2024-01-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bortezomib | Small molecule | — | Subcutaneous |
| Subject | Dexamethasone | Small molecule | — | Oral |
| Subject | Elotuzumab | Monoclonal antibody | — | Intravenous |
| Subject | Lenalidomide | Other / unclassified | — | Oral |